catenabio.com

Home - CatenaBio

  • ️Mon Nov 06 2023

Alert: Unauthorized individuals have been falsely claiming to represent CatenaBio. Learn more

Because sometimes biology isn’t enough.

Building with biologics should be as easy as building with small molecules.

Today, we can't make the medicines we’d like to, because current approaches to building biologic structures are limited.

About CatenaBio

Imagine if you could:

Take any antibody-drug conjugate (ADC) and add additional therapeutic modalities

Take any antibody and attach functional cytokines

Attach a targeting protein to the surface of any cell without genetic editing

Breakthrough Protein Conjugation

CatenaBio’s CysTyr platform utilizes the novel Catenase enzyme, which catalyzes the formation of our proprietary C-Y Bond using only native amino acids.

Our approach eliminates the current size and complexity constraints that restrict molecule connections. This allows attachment of multiple different cargoes to a protein, delivering new therapeutic modalities.

All this is accomplished with greater speed, stability, selectivity, and scalability than current approaches.

Explore the science

A molecule with an inactivated n- or c-terminal tyrosine.

Our approach eliminates the current size and complexity constraints that restrict molecule connections. This allows attachment of multiple different cargoes to a protein, delivering new therapeutic modalities.

All this is accomplished with greater speed, stability, selectivity, and scalability than current approaches.

Explore the science

A molecule with an inactivated n- or c-terminal tyrosine.

A molecule conjugated with a second molecule using the C-Y bond

Exceptional Minds
Exceptional Innovation

Our team has been instrumental in advancing medical research. Our technology was developed in the same halls where CRISPR was born, a connection that fuels our passion for pushing the boundaries of scientific discovery.

Meet our team

Our Pipeline:
Transforming the ADC Market Through Revolutionary
Multi-Payload Conjugate Technology

View our pipeline

CatenaBio News

CatenaBio Presents Poster on Multi-Payload Conjugates at the American Association for Cancer Research (AACR) Annual Meeting

April 8, 2024  |  San Diego, CA

CatenaBio Selected to Present on its Next Generation Platform and Multi Payload Conjugates (MPC®) at the Berkeley Bio Startup Showcase @JPM

January 4, 2024  |  Berkeley, CA